UB Paderborn / Katalog / Suche / in CDI

Risk of imminent fracture following a previous fracture in a Swedish database study

Osteoporosis international, 2019-03, Vol.30 (3), p.601-609

2019

Link zum Volltext

Verfügbarkeit prüfen

Denosumab for Prevention of Fractures in Postmenopausal Women with Osteoporosis

The New England journal of medicine, 2009-08, Vol.361 (8), p.756-765

2009

Link zum Volltext

Verfügbarkeit prüfen

Bone mineral density gains with a second 12-month course of romosozumab therapy following placebo or denosumab

Osteoporosis international, 2019-12, Vol.30 (12), p.2437-2448

2019

Link zum Volltext

Verfügbarkeit prüfen

The effect of 8 or 5 years of denosumab treatment in postmenopausal women with osteoporosis: results from the FREEDOM Extension study

Osteoporosis international, 2015-12, Vol.26 (12), p.2773-2783

2015

Link zum Volltext

Verfügbarkeit prüfen

Five years of denosumab exposure in women with postmenopausal osteoporosis: Results from the first two years of the FREEDOM extension

Journal of bone and mineral research, 2012-03, Vol.27 (3), p.694-701

2012

Link zum Volltext

Verfügbarkeit prüfen

Romosozumab in patients who experienced an on-study fracture: post hoc analyses of the FRAME and ARCH phase 3 trials

Osteoporosis international, 2024-04

2024

Link zum Volltext

Verfügbarkeit prüfen

Secular trends in the initiation of therapy in secondary fracture prevention in Europe: a multi-national cohort study including data from Denmark, Catalonia, and the United Kingdom

Osteoporosis international, 2020-08, Vol.31 (8), p.1535-1544

2020

Link zum Volltext

Verfügbarkeit prüfen

Relationship Between Bone Mineral Density T‐Score and Nonvertebral Fracture Risk Over 10 Years of Denosumab Treatment

Journal of bone and mineral research, 2019-06, Vol.34 (6), p.1033-1040

2019

Link zum Volltext

Verfügbarkeit prüfen

The treatment gap after major osteoporotic fractures in Denmark 2005-2014: a combined analysis including both prescription-based and hospital-administered anti-osteoporosis medications

Osteoporosis international, 2021-10, Vol.32 (10), p.1961-1971

2021

Link zum Volltext

Verfügbarkeit prüfen

National Bone Health Alliance Bone Turnover Marker Project: current practices and the need for US harmonization, standardization, and common reference ranges

Osteoporosis international, 2012-10, Vol.23 (10), p.2425-2433

2012

Link zum Volltext

Verfügbarkeit prüfen

Unmasking romosozumab: response to commentsby Uzoigwe et al

Osteoporosis international, 2017-06, Vol.28 (6), p.2021-2022

2017

Link zum Volltext

Verfügbarkeit prüfen

Effect of denosumab on trabecular bone score in postmenopausal women with osteoporosis

Osteoporosis international, 2017-10, Vol.28 (10), p.2967-2973

2017

Link zum Volltext

Verfügbarkeit prüfen

A novel economic framework to assess the cost-effectiveness of bone-forming agents in the prevention of fractures in patients with osteoporosis

Osteoporosis international, 2021-07, Vol.32 (7), p.1301-1311

2021

Link zum Volltext

Verfügbarkeit prüfen

Further reductions in nonvertebral fracture rate with long-term denosumab treatment in the FREEDOM open-label extension and influence of hip bone mineral density after 3 years

Osteoporosis international, 2015-12, Vol.26 (12), p.2763-2771

2015

Link zum Volltext

Verfügbarkeit prüfen

Advanced CT based In Vivo Methods for the Assessment of Bone Density, Structure, and Strength

Current osteoporosis reports, 2013-09, Vol.11 (3), p.246-255

2013

Link zum Volltext

Verfügbarkeit prüfen

Long-term denosumab treatment restores cortical bone loss and reduces fracture risk at the forearm and humerus: analyses from the FREEDOM Extension cross-over group

Osteoporosis international, 2019-09, Vol.30 (9), p.1855-1864

2019

Link zum Volltext

Verfügbarkeit prüfen

Short-Term Fracture (Fx) Incidence And Risk Factors Following Fracture In A Swedish Database Study

OSTEOPOROSIS INTERNATIONAL, 2017, Vol.28, p.S365

2017

Link zum Volltext

Verfügbarkeit prüfen

Denosumab improves density and strength parameters as measured by QCT of the radius in postmenopausal women with low bone mineral density

Bone (New York, N.Y.), 2010-07, Vol.47 (1), p.131-139

2010

Link zum Volltext

Verfügbarkeit prüfen

Romosozumab Treatment in Postmenopausal Women with Osteoporosis

The New England journal of medicine, 2016-10, Vol.375 (16), p.1532-1543

2016

Link zum Volltext

Verfügbarkeit prüfen

Comorbidity indices for clinical trials: adaptation of two existing indices for use with the FREEDOM trial in women with postmenopausal osteoporosis

Osteoporosis international, 2016-01, Vol.27 (1), p.75-80

2016

Link zum Volltext

Verfügbarkeit prüfen

Risk of Major Osteoporotic Fracture (Hip, Vertebral, Radius, Humerus [MOF]) After First, Second and Third Fragility Fracture In A Swedish General Population Cohort

VALUE IN HEALTH, 2017-10, Vol.20 (9), p.A528

2017

Link zum Volltext

Verfügbarkeit prüfen

OP0100 Superior Gains in Bone Mineral Density and Estimated Strength at The Hip for Romosozumab Compared with Teriparatide in Women with Postmenopausal Osteoporosis Transitioning from Bisphosphonate Therapy: Results of The Phase 3 Open-Label Structure Study

Annals of the rheumatic diseases, 2016-06, Vol.75 (Suppl 2), p.92-93

2016

Link zum Volltext

Verfügbarkeit prüfen

Denosumab Treatment Is Associated With Progressive Improvements in Cortical Mass and Thickness at the Hip in Regions Relevant to Fracture Protection

Journal of clinical densitometry, 2013-07, Vol.16 (3), p.266-267

2013

Link zum Volltext

Verfügbarkeit prüfen

OP0291 Romosozumab Administration is Associated with Significant Improvements in Lumbar Spine and Hip Volumetric Bone Mineral Density and Content Compared with Teriparatide

Annals of the rheumatic diseases, 2014-06, Vol.73 (Suppl 2), p.172-172

2014

Link zum Volltext

Verfügbarkeit prüfen

SAT0457 Reduced Hip Cortical Porosity with Denosumab (DMAB) Treatment in Women with Osteoporosis

Annals of the rheumatic diseases, 2014-06, Vol.73 (Suppl 2), p.759-759

2014

Link zum Volltext

Verfügbarkeit prüfen

Menü

Weitere Dienste

Einstellungen

Risk of imminent fracture following a previous fracture in a Swedish database study

Denosumab for Prevention of Fractures in Postmenopausal Women with Osteoporosis

Bone mineral density gains with a second 12-month course of romosozumab therapy following placebo or denosumab

The effect of 8 or 5 years of denosumab treatment in postmenopausal women with osteoporosis: results from the FREEDOM Extension study

Five years of denosumab exposure in women with postmenopausal osteoporosis: Results from the first two years of the FREEDOM extension

Romosozumab in patients who experienced an on-study fracture: post hoc analyses of the FRAME and ARCH phase 3 trials

Secular trends in the initiation of therapy in secondary fracture prevention in Europe: a multi-national cohort study including data from Denmark, Catalonia, and the United Kingdom

Relationship Between Bone Mineral Density T‐Score and Nonvertebral Fracture Risk Over 10 Years of Denosumab Treatment

The treatment gap after major osteoporotic fractures in Denmark 2005-2014: a combined analysis including both prescription-based and hospital-administered anti-osteoporosis medications

National Bone Health Alliance Bone Turnover Marker Project: current practices and the need for US harmonization, standardization, and common reference ranges

Unmasking romosozumab: response to commentsby Uzoigwe et al

Effect of denosumab on trabecular bone score in postmenopausal women with osteoporosis

A novel economic framework to assess the cost-effectiveness of bone-forming agents in the prevention of fractures in patients with osteoporosis

Further reductions in nonvertebral fracture rate with long-term denosumab treatment in the FREEDOM open-label extension and influence of hip bone mineral density after 3 years

Advanced CT based In Vivo Methods for the Assessment of Bone Density, Structure, and Strength

Long-term denosumab treatment restores cortical bone loss and reduces fracture risk at the forearm and humerus: analyses from the FREEDOM Extension cross-over group

Short-Term Fracture (Fx) Incidence And Risk Factors Following Fracture In A Swedish Database Study

Denosumab improves density and strength parameters as measured by QCT of the radius in postmenopausal women with low bone mineral density

Romosozumab Treatment in Postmenopausal Women with Osteoporosis

Comorbidity indices for clinical trials: adaptation of two existing indices for use with the FREEDOM trial in women with postmenopausal osteoporosis

Risk of Major Osteoporotic Fracture (Hip, Vertebral, Radius, Humerus [MOF]) After First, Second and Third Fragility Fracture In A Swedish General Population Cohort

OP0100 Superior Gains in Bone Mineral Density and Estimated Strength at The Hip for Romosozumab Compared with Teriparatide in Women with Postmenopausal Osteoporosis Transitioning from Bisphosphonate Therapy: Results of The Phase 3 Open-Label Structure Study

Denosumab Treatment Is Associated With Progressive Improvements in Cortical Mass and Thickness at the Hip in Regions Relevant to Fracture Protection

OP0291 Romosozumab Administration is Associated with Significant Improvements in Lumbar Spine and Hip Volumetric Bone Mineral Density and Content Compared with Teriparatide

SAT0457 Reduced Hip Cortical Porosity with Denosumab (DMAB) Treatment in Women with Osteoporosis

Suchergebnisse filtern